Glymphatic dysfunction in Parkinson's disease: Aging-associated impairments, imaging biomarkers, and therapeutic strategies

Dec 14, 2025Ageing research reviews

Impaired brain waste clearance in Parkinson's disease: age-related problems, imaging signs, and possible treatments

AI simplified

Regenerative Health on OpenScience ↗PubMed ↗DOI ↗

Abstract

Glymphatic dysfunction is associated with impaired α-synuclein clearance in Parkinson's disease.

Impaired clearance mechanisms contribute to the accumulation of α-synuclein in Parkinson's disease.
Disrupted aquaporin-4 polarization, reduced meningeal lymphatic drainage, and sleep disturbances may collectively hinder glymphatic flow.
These factors are linked to increased α-synuclein aggregation and loss of dopaminergic neurons.
Neuroimaging techniques like the DTI-ALPS index and measurements of enlarged perivascular spaces correlate with motor severity and cognitive decline.
Potential therapeutic approaches include photobiomodulation and sleep interventions, although clinical translation of these strategies is still limited.

AI simplified

The accumulation of α-synuclein (α-syn) is a key pathophysiological feature of Parkinson's disease (PD), and one contributing factor to this aggregation is impaired clearance mechanisms. Recent research has identified the glymphatic system as the brain's intrinsic waste clearance pathway. This review examines glymphatic dysfunction in PD, with a focus on its impact on α-syn clearance and neurodegeneration. We summarize current evidence showing that disrupted aquaporin-4 (AQP4) polarization, reduced meningeal lymphatic drainage, and sleep disturbances collectively impair glymphatic flow, thereby promoting α-syn aggregation and dopaminergic neuronal loss. We also review emerging neuroimaging approaches, including the Diffusion Tensor Imaging Analysis Along the Perivascular Space (DTI-ALPS) index, enlarged perivascular spaces (EPVSs) and choroid plexus volume (CPV), which increasingly enable in vivo evaluation of glymphatic dysfunction and show correlations with motor severity and cognitive decline. In addition, we discuss potential therapeutic approaches aimed at restoring glymphatic function, including photobiomodulation, pharmacological AQP4 modulation, sleep based interventions, and surgical interventions like deep cervical lymphaticovenular anastomosis (dcLVA). Although these strategies show promise in preclinical studies, their clinical translation remains limited. By integrating insights from glymphatic biology, neuroimaging, and therapeutic development, this review highlights new avenues for PD management and underscores the glymphatic system as a promising therapeutic target for modifying disease progression.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Glymphatic dysfunction in Parkinson's disease: Aging-associated impairments, imaging biomarkers, and therapeutic strategies

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week: